Giuseppe Curigliano, PhD
Giuseppe Curigliano, MD PhD, is Full Professor of Medical Oncology at the University of Milano and head of the Clinical Division of Early Drug Development at European Institute of Oncology, Milano, Italy.
Dr. Curigliano is an expert in the field of advanced drug development in solid tumors, with specific interest on breast cancer. His clinical activity is based on the genetic characterization of tumors and on testing new experimental drugs specific for particular groups of patients. He contributed to the development of many anticancer treatments actually available as standard of care in the treatment of multiple solid tumors. Since 2001 he is tenure-track and full-time cancer specialist at European Institute of Oncology – one of the world’s leading cancer-research institutes and the premier Cancer Center in Italy and third in Europe. He serves as member of the Italian Higher Council Health.
Dr. Curigliano serves ESMO as Chair of the Clinical Practice Guidelines Committee. He was awarded with the first ESO Umberto Veronesi Award in Vienna in 2017 and with the Fellowship of the European Academy of Cancer Sciences in Paris in 2017. Dr. Curigliano in 2022 was identified as Clarivate™ world’s most influential researchers, and has contributed to over 600 peer-reviewed publications.
Professor of Medical Oncology at Università degli studi di Milano, La Statale, IT
Head of the Division of Early Drug Development at the European Institute of Oncology, IT
Scientific Board Member
Università di Milano